168 related articles for article (PubMed ID: 38044665)
21. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
Fredriksen M; Peleikis DE
Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
[TBL] [Abstract][Full Text] [Related]
23. Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis.
Pan PY; Jonsson U; Şahpazoğlu Çakmak SS; Häge A; Hohmann S; Nobel Norrman H; Buitelaar JK; Banaschewski T; Cortese S; Coghill D; Bölte S
Psychol Med; 2022 Jan; 52(1):14-25. PubMed ID: 34635194
[TBL] [Abstract][Full Text] [Related]
24. First episode psychosis and comorbid ADHD, autism and intellectual disability.
Strålin P; Hetta J
Eur Psychiatry; 2019 Jan; 55():18-22. PubMed ID: 30384107
[TBL] [Abstract][Full Text] [Related]
25. Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder.
Sultan RS; Wang S; Crystal S; Olfson M
JAMA Netw Open; 2019 Jul; 2(7):e197850. PubMed ID: 31348506
[TBL] [Abstract][Full Text] [Related]
26. [Risk of psychosis with treatment for ADHD].
Kooij JJS
Ned Tijdschr Geneeskd; 2020 Aug; 164():. PubMed ID: 32940981
[TBL] [Abstract][Full Text] [Related]
27. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Gibson AP; Bettinger TL; Patel NC; Crismon ML
Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
[TBL] [Abstract][Full Text] [Related]
28. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
29. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
[TBL] [Abstract][Full Text] [Related]
30. The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression.
Liang EF; Lim SZ; Tam WW; Ho CS; Zhang MW; McIntyre RS; Ho RC
Int J Environ Res Public Health; 2018 Aug; 15(8):. PubMed ID: 30127314
[TBL] [Abstract][Full Text] [Related]
31. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
[TBL] [Abstract][Full Text] [Related]
32. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis.
Hanwella R; Senanayake M; de Silva V
BMC Psychiatry; 2011 Nov; 11():176. PubMed ID: 22074258
[TBL] [Abstract][Full Text] [Related]
34. Successful Management of Methylphenidate or Atomoxetine-Related Priapism During Attention-Deficit Hyperactivity Disorder Treatment.
Karayagmurlu A; Coskun M
J Clin Psychopharmacol; 2020; 40(3):314-315. PubMed ID: 32332473
[No Abstract] [Full Text] [Related]
35. Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments.
Jordan CJ; Harvey RC; Baskin BB; Dwoskin LP; Kantak KM
Drug Alcohol Depend; 2014 Jul; 140():25-32. PubMed ID: 24811203
[TBL] [Abstract][Full Text] [Related]
36. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.
Moran LV; Ongur D; Hsu J; Castro VM; Perlis RH; Schneeweiss S
N Engl J Med; 2019 Mar; 380(12):1128-1138. PubMed ID: 30893533
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
Liu Q; Zhang H; Fang Q; Qin L
J Clin Exp Neuropsychol; 2017 Nov; 39(9):854-865. PubMed ID: 28052720
[TBL] [Abstract][Full Text] [Related]
38. Treatment of attention deficit/hyperactivity disorder in children with CHD.
Pierick AR; Lynn M; McCracken CM; Oster ME; Iannucci GJ
Cardiol Young; 2021 Jun; 31(6):969-972. PubMed ID: 33517944
[TBL] [Abstract][Full Text] [Related]
39. Caregiver survey of pharmacotherapy to treat attention deficit/hyperactivity disorder in individuals with Williams syndrome.
Martens MA; Seyfer DL; Andridge RR; Foster JE; McClure KE; Coury DL
Res Dev Disabil; 2013 May; 34(5):1700-9. PubMed ID: 23500164
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacological management of attention deficit hyperactivity disorder with methylphenidate and atomoxetine within a context of epilepsy].
Mulas F; Roca P; Ros-Cervera G; Gandía-Benetó R; Ortiz-Sánchez P
Rev Neurol; 2014 Feb; 58 Suppl 1():S43-9. PubMed ID: 25252667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
